Ozempic Is About to Go Generic in India, China and Canada

The New York Times – Business:

In India, China and several other nations, Novo Nordisk is on the verge of losing patent protection for its blockbuster weight loss drug, opening the door for cheaper competing versions.

Author: RSS Feed

This post first appeared in The New York Times – Business. Read the original article.